[DRP] - I L - Atezolizumab / Durwalumab 07.2025 [MIĘDZYBŁONIAK] Niwolumab + Ipiliumab 07.2025 [NDRP] - ADIUWANT - ALK 07.2025 [NDRP] - ADIUWANT - Atezolizumab 07.2025 [NDRP] - ADIUWANT - Ozymertynib 07.2025 [NDRP] - ADIUWANT - Pembrolizumab 07.2025 [NDRP] - I L - immunoterapia +/- chemioterapia 07.2025 [NDRP] - I L - Afatynib / Ozymertynib 07.2025 [NDRP] - II+ L -  Nintendanib + chemioterapia 07.2025 [NDRP] - II+ L - Ozymertynib 07.2025 [NDRP] - II+ L - Sotorasib 07.2025 [NDRP] - II+L - Atezolizumab / Niwolumab 07.2025 [NDRP] - KONSOLIDACJA - Durwalumab 07.2025 [NDRP] - NEOADIUWANT - Nivolumab + chemioterapia 07.2025 [NDRP] - OKOŁOOPER. - Pembrolizumab + chemioterapia 07.2025 [NDRP] - PALIATYWNE - ALK/ROS-1 07.2025